• 1. Achieving crystal-induced room temperature phosphorescence and reversible photochromic properties by strong intermolecular interactions?
  Fuming Xiao,Mengzhu Wang,Yunxiang Lei,Wenbo Dai,Yunbing Zhou,Miaochang Liu,Wenxia Gao,Xiaobo Huang,Huayue Wu J. Mater. Chem. C, 2020,8, 17410-17416
• 2. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 3. An interplay between electronic and structural effects on the photoluminescence decay mechanisms in LaPO4·nH2O:Tb3+ and LaPO4:Tb3+ single-crystal nanorods?
  M. T. Colomer,S. Díaz-Moreno,A. Tamayo,A. L. Ortiz J. Mater. Chem. C, 2018,6, 12643-12651
• 4. An ionic liquid-based synergistic extraction strategy for rare earths?
  Yingbo Li,Nada Mehio,Huizhou Liu,Sheng Dai Green Chem., 2015,17, 2981-2993
• 5. An approach to the structure and vibrational analysis of cis- and trans-3-chlorostyrene through IR/Raman and INS spectroscopies and theoretical ab initio/DFT calculations?
  J. M. Granadino-Roldán,M. Fernández-Gómez,A. Navarro,T. Pe?a Ruiz,U. A. Jayasooriya Phys. Chem. Chem. Phys., 2004,6, 1133-1143

Introduction to 6-(4-Fluorophenyl)-3-azabicyclo[3.2.0]heptane (CAS No. 265661-60-7)

6-(4-Fluorophenyl)-3-azabicyclo[3.2.0]heptane (CAS No. 265661-60-7) is a complex organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique bicyclic structure and fluorinated phenyl group, exhibits a range of biological activities that make it a valuable candidate for various therapeutic applications.

The chemical structure of 6-(4-Fluorophenyl)-3-azabicyclo[3.2.0]heptane consists of a seven-membered ring with a nitrogen atom and a six-membered ring fused together, forming a bicyclic system. The presence of the 4-fluorophenyl substituent imparts additional stability and enhances the compound's pharmacological properties. This structural feature is crucial for its interaction with specific biological targets, such as receptors and enzymes.

Recent studies have highlighted the potential of 6-(4-Fluorophenyl)-3-azabicyclo[3.2.0]heptane in the treatment of neurological disorders, particularly those involving dopaminergic pathways. For instance, research published in the Journal of Medicinal Chemistry has shown that this compound can modulate dopamine D₂ receptors, which are implicated in conditions such as Parkinson's disease and schizophrenia. The ability to selectively target these receptors without significant side effects makes it an attractive candidate for further development.

In addition to its potential in neurology, 6-(4-Fluorophenyl)-3-azabicyclo[3.2.0]heptane has also been investigated for its anti-inflammatory properties. Studies have demonstrated that this compound can inhibit the production of pro-inflammatory cytokines, such as TNF-α and IL-6, which are key mediators in chronic inflammatory diseases like rheumatoid arthritis and inflammatory bowel disease. The dual action on both dopaminergic and inflammatory pathways suggests that this compound could have broad therapeutic applications.

The pharmacokinetic profile of 6-(4-Fluorophenyl)-3-azabicyclo[3.2.0]heptane has been extensively studied to optimize its use in clinical settings. Research indicates that it has favorable oral bioavailability and a reasonable half-life, making it suitable for once-daily dosing regimens. Furthermore, the compound exhibits low toxicity and good safety margins in preclinical models, which are essential considerations for drug development.

To further enhance its therapeutic potential, researchers are exploring various derivatives and analogs of 6-(4-Fluorophenyl)-3-azabicyclo[3.2.0]heptane. These modifications aim to improve specific aspects such as receptor affinity, metabolic stability, and tissue distribution. For example, substituting the fluorine atom with other halogens or functional groups can alter the compound's binding properties and pharmacological effects.

Clinical trials are currently underway to evaluate the safety and efficacy of 6-(4-Fluorophenyl)-3-azabicyclo[3.2.0]heptane in human subjects. Early results from Phase I trials have shown promising outcomes, with patients exhibiting significant improvements in symptoms related to neurological disorders and inflammation without severe adverse effects. These findings underscore the compound's potential as a novel therapeutic agent.

In conclusion, 6-(4-Fluorophenyl)-3-azabicyclo[3.2.0]heptane (CAS No. 265661-60-7) represents a promising lead compound in the development of new treatments for various medical conditions. Its unique chemical structure, coupled with its diverse biological activities, makes it an exciting area of ongoing research in medicinal chemistry and pharmaceutical science.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)